Evidence map›Paper›PMID 39471029›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Adherence to Oral Hormonal Treatment among Breast Cancer Patients in Egypt.

Noha Salaheldin ElBaghdady, May Mohamed El Gazzar, Abdelrahman Magdy Abdo, Ahmed Mohamed Magdy, Farha Abdelghaffar Youssef, Kareem Amr Sayed, Mohamed Mahmoud Hussein, Joseph Essam Megala, Salma Hossam Eldien, Zeyad Mohsen Elmaboud and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Noha Salaheldin ElBaghdadyClinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
May Mohamed El GazzarNational Cancer Institute, Breast Cancer Hospital, The First Settlement, Cairo, Egypt.
Abdelrahman Magdy AbdoFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Ahmed Mohamed MagdyFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Farha Abdelghaffar YoussefFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Kareem Amr SayedFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Mohamed Mahmoud HusseinFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Joseph Essam MegalaFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Salma Hossam EldienFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Zeyad Mohsen ElmaboudFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Hesham Mohamed MostafaFaculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt.
Nada H FarragClinical Pharmacy Practice Department, School of life and Medical Sciences, University of Hertfordshire, hosted by Global Academic Foundation. Plot Code No 6, R5, New Administrative Capital, Cairo, Egypt.ORCID 0000-0001-9567-0688

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdjuvant endocrine therapy has been shown to improve treatment outcomes in breast cancer patients. However, not all patients can complete their scheduled treatment protocols. The purpose of this study was to evaluate the adherence to oral hormonal therapy among Egyptian breast cancer patients. PATIENTS AND

methodsA cross-sectional study was conducted at the National Cancer Institute, Breast Cancer Hospital, from February 2022 to May 2022. An interview and a survey were administered to assess the adherence of breast cancer patients to oral hormonal treatment. Adherence was measured using the Morisky Medication Adherence Scale-8 (MMAS-8).

resultsThe survey was fully completed by 300 patients, of whom 98.3% were females and 1.7% were males. Among the patients, 30% fell into the age group of 40-50 years. Most patients were postmenopausal (90.3%). In terms of education, 18% had a high level of education, while 53.3% were illiterate. Additionally, 50.7% of patients had other chronic diseases. Regarding medication information, 44.7% preferred to receive it from a physician, 27.7% from pharmacists, and 27.7% from both. Proper medication counseling was received by 99.7% of patients. According to the MMAS-8 survey, 40.3% of all patients demonstrated high adherence to their oral hormonal treatment, 32.7% had moderate adherence, and 27% had low adherence. No significant associations were found between adherence levels and subgroups such as gender, age, educational level, duration of endocrine therapy, breast cancer stage, or other co-morbidities.

conclusionThis study reveals a substantial level of adherence, both high and moderate, to oral endocrine therapy among breast cancer patients in Egypt. Possible contributing factors include proper medication counseling within the healthcare setting and regular patient follow-up.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsDrug MonitoringAdministration, OralAdultAgedCross-Sectional StudiesEgyptFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisSurveys and QuestionnairesAntineoplastic Agents, Hormonalaromatase inhibitorbreast cancerKeywords: AdherenceTamoxifen

Identifiers

PMID39471029
PMCPMC11711348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.